ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
Excellent balance sheet and overvalued.
Share Price & News
How has ImmuCell's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IUL has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IUL underperformed the German Biotechs industry which returned -2.9% over the past year.
Return vs Market: IUL underperformed the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is ImmuCell's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ImmuCell undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IUL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IUL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IUL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IUL is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IUL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IUL is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).
How is ImmuCell forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmuCell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine ImmuCell's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ImmuCell competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has ImmuCell performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IUL is currently unprofitable.
Growing Profit Margin: IUL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IUL is unprofitable, and losses have increased over the past 5 years at a rate of -63.2% per year.
Accelerating Growth: Unable to compare IUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IUL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: IUL has a negative Return on Equity (-4.44%), as it is currently unprofitable.
How is ImmuCell's financial position?
Financial Position Analysis
Short Term Liabilities: IUL's short term assets ($13.6M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: IUL's short term assets ($13.6M) exceed its long term liabilities ($7.4M).
Debt to Equity History and Analysis
Debt Level: IUL's debt to equity ratio (29.9%) is considered satisfactory.
Reducing Debt: IUL's debt to equity ratio has increased from 10.1% to 29.9% over the past 5 years.
Inventory Level: IUL has a high level of physical assets or inventory.
Debt Coverage by Assets: IUL's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IUL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IUL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -31.5% each year.
What is ImmuCell's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IUL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IUL's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Brigham (58yo)
Mr. Michael F. Brigham has been the Chief Executive Officer and President of Immucell Corp. since February 2000 and its Principal Financial Officer and Treasurer since October 1991. Mr. Brigham has been Se ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD426.28K) is about average for companies of similar size in the German market ($USD419.45K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
|VP & Chief Scientific Officer||21.4yrs||US$62.00k||1.97% $628.1k|
|VP of Sales & Marketing and Director||2.1yrs||US$291.84k||0.052% $16.7k|
|Vice President of Manufacturing Operations||3.8yrs||US$273.53k||no data|
Experienced Management: IUL's management team is seasoned and experienced (12.5 years average tenure).
|VP of Sales & Marketing and Director||2.1yrs||US$291.84k||0.052% $16.7k|
|Independent Director||18.8yrs||US$71.85k||7.08% $2.3m|
|Independent Director||5.9yrs||US$71.85k||0.087% $27.8k|
|Independent Director||8.4yrs||US$71.85k||0.18% $57.6k|
|Independent Director||2.1yrs||US$65.85k||no data|
Experienced Board: IUL's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.
ImmuCell Corporation's company bio, employee growth, exchange listings and data sources
- Name: ImmuCell Corporation
- Ticker: IUL
- Exchange: DB
- Founded: 1982
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$35.111m
- Listing Market Cap: US$31.926m
- Shares outstanding: 7.21m
- Website: https://immucell.com
Number of Employees
- ImmuCell Corporation
- 56 Evergreen Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ICCC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||May 1987|
|IUL||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1987|
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 22:03|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.